Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction

Arthritis and Rheumatism

Volumn 41, Issue 1, 1998, Pages 110-121

  Mudgett, J S ^a   Hutchinson, N I ^a   Chartrain, N A ^a   Forsyth, A J ^a   Mcdonnell, J ^a   Singer, I I ^a   Bayne, E K ^a   Flanagan, J ^a   Kawka, D ^a   Shen, C F ^a   Stevens, K ^a   Chen, H ^a   Trumbauer, M ^a   Visco, D M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; ASPARAGINE; COLLAGEN; EPITOPE; PHENYLALANINE; PROTEOGLYCAN; STROMELYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; CONTROLLED STUDY; EMBRYO; ENZYME DEFICIENCY; GENE DISRUPTION; GENE TARGETING; GENETIC RECOMBINATION; GENETIC SUSCEPTIBILITY; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; BLOTTING, NORTHERN; CARTILAGE, ARTICULAR; COLLAGEN; EPITOPES; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 3; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOARTHRITIS; PHENOTYPE; RNA, MESSENGER; STEM CELLS;

EID: 14444285039     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G     Document Type: Article

References (74)

1. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
2. Hasty KA, Reife RA, Kang AH, Stuart JM. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 1990;33:388-97.
3. Brinckerhoff CE. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum 1991;34:1073-5.
4. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier J-M, Pelletier J-P. Excess of metalloproteinases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15.
5. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992;267:3581-4.
6. Okada Y, Nagase H, Harris ED. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. J Biol Chem 1986;261:14245-55.
7. Okada Y, Konomi H, Yada T, Kimata K, Nagase H. Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells. FEBS Lett 1989;244:473-6.
8. Case JP, Lafyatis R, Remmers EF, Kumkumian GK, Wilder RL. Transin/stromelysin expression in rheumatoid synovium: a transformation-associated metalloproteinase secreted by phenotypically invasive synoviocytes. Am J Pathol 1989;135:1055-64.
9. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. J Biol Chem 1990;265:17238-45.
10. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076-84.
11. Okada Y, Shinmei M, Tanaka O, Naka K, Kimura A, Nakanishi I, et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992;66:680-90.
12. Tetlow LC, Lees M, Ogata Y, Nagase H, Woolley DE. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int 1993;13:53-9.
13. Wolfe GC, MacNaul KL, Beuchel FF, McDonnell J, Hoerrner LA, Lark MW, et al. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage: quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis. Arthritis Rheum 1993;36:1540-7.
14. Case JP, Sano H, Lafyatis R, Remmers EF, Kumkumian GK, Wilder RL. Transin/stromelysin expression in the synovium of rats with experimental erosive arthritis: in situ localization and kinetics of expression on the transformation-associated metalloproteinase in euthymic and athymic Lewis rats. J Clin Invest 1989;84:1731-40.
15. Pelletier JP, Faure JA, DiBattista JA, Wilhelm S, Visco DM, Martel-Pelletier L. Coordinate synthesis of stromelysin, interleukin-1, and oncogene proteins in experimental osteoarthritis: an immunohistochemical study. Am J Pathol 1993;142:95-105.
16. Mehraban F, Kuo S-Y, Riera H, Chang C, Moskowitz RW. Prostromelysin and procollagenase genes are differentially upregulated in chondrocytes from the knees of rabbits with experimental osteoarthritis. Arthritis Rheum 1994;37:1189-97.
17. Carmichael DF, Stricklin GP, Stuart JM. Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice. Agents Actions 1989;27:378-9.
18. Gordon JL, Drummond AH, Galloway WA. Metalloproteinase inhibitors as therapeutics. Clin Exp Rheumatol 1993;11 Suppl 8:S91-4.
19. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis: easier said than done? Arthritis Rheum 1994;37:1115-26.
20. Courtenay JS, Dallman MJ, Dayan AD, Marten A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
21. Stuart JM, Cremer MA, Kang AH, Townes AS. Collagen-induced arthritis in rats: evaluation of early immunologic events. Arthritis Rheum 1979;22:1344-51.
22. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146:857-68.
23. Trentham DE. Collagen arthritis as a relevant model for rheumatoid arthritis: evidence pro and con. Arthritis Rheum 1982; 25:911-6.
24. Terato K, Hashida R, Miyamoto K, Morimoto T, Kata Y, Kobayashi S, et al. Histological, immunological, and biochemical studies on type II collagen-induced arthritis in rats. Biomed Res 1982;3:495-523. /
25. Reife RA, Hasty KA, Mainardi CL, Stuart JM. Immunolocalization of metalloproteinases in collagen autoimmune arthritis [Abstract]. Matrix 1992;S1:397.
26. Fosang AJ, Last K, Knauper V, Neame PJ, Murphy G, Hardingham TE, et al. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J 1993;295:273-6.
27. Fosang AJ, Neame PJ, Hardingham TE, Murphy G, Hamilton JA. Cleavage of cartilage proteoglycan between g1 and g2 domains by stromelysins. J Biol Chem 1991;266:15579-82.
28. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992;267:19470-4.
29. Fosang AJ, Last K, Neame PJ, Hughes CE, Caterson B, Hardingham TE, et al. Neutrophil collagenase cleaves the aggrecanase site in the interglobular region of aggrecan [Abstract]. Trans Orthop Res Soc 1994;19:48.
30. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan: evidence for proteolysis at this site in-vivo in human articular cartilage. J Biol Chem 1992;267:1008-14.
31. Lark MW, Williams H, Hoernner LA, Weidner J, Ayala JM, Harper CF, et al. Quantification of a matrix metalloproteinase-generated agarecan G1 fragment using monospecific anti-peptide serum. Biochem J 1995;307:245-52.
32. Singer II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HR, et al. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 1995;95:2178-86.
33. Bayne EK, Donatelii SA, Singer II, Weidner JR, Hutchinson NI, Hoerner LA, et al. Detection of a metalloproteinase-generated aggrecan HABR fragment within human OA and RA cartilage [Abstract]. Trans Orthop Res Soc 1994;19:308.
34. Bayne EK, MacNaul KL, Donatelli SA, Christen A, Griffin PR, Hoerrner LA, et al. Use of an antibody against the matrix metalloproteinase-generated aggrecan neoepitope FVDIPENCOOH to assess the effects of stromelysin in a rabbit model of cartilage degradation. Arthritis Rheum 1995;38:1400-9.
35. Ostrowski LE, Finch J, Krieg P, Matrisian L, Patskan G, O'Connell FF, et al. Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression. Mol Carcinog 1988;1:13-9.
36. Mudgett JS, Livelli TJ. Electroporation of ES cells for generating transgenic mice and studying in vitro differentiation. Methods Mol Biol 1995;48:167-84.
37. Hutchinson NI, Lark MW, MacNaul KL, Harper C, Hoerrner LA, McDonnell J, et al. In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1β. Arthritis Rheum 1992;35:1227-33.
38. Wooley PH. Collagen-induced arthritis in the mouse. Methods Enzymol 1988;162:361-73.
39. McLean IW, Nakane PK. Periodate-lysine-paraformaldehyde fixative: a new fixation for immunoelectron microscopy. J Histochem Cytochem 1974;22:1077-83.
40. Getzy LL, Malemud CJ, Goldberg VM, Moskowitz RW. Factors influencing metachromatic staining in paraffin-embedded section of rabbit and human articular cartilage: a comparison of the Safranin O and Toluidine blue O techniques. J Histotechnol 1982;5:111-6.
41. Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal rheumatoid and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989;83:647-61.
42. Shu S, Ju G, Fan L. The glucose oxidase-DAB nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett 1988;85:169-71.
43. Adler RR, Brenner CA, Werb Z. Expression of extracellular matrix-degrading metalloproteinases and metalloproteinase inhibitors is developmentally regulated during endoderm differentiation of embryonal carcinoma cells. Development 1990;110:211-20.
44. Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 1992;118:1271-82.
45. Li F, Strange R, Friis RR, Djonov V, Altermatt H-J, Saurer S, et al. Expression of stromelysin-1 and TIMP-1 in the involuting mammary gland and in early invasive tumors of the mouse. Int J Cancer 1994;59:560-8.
46. Mauch C, Krieg T, Bauer EA. Role of the extracellular matrix in the degradation of connective tissue. Arch Dermatol Res 1994;287:107-14.
47. Sirum KL, Brinckerhoff CE. Cloning of the genes for human stromelysin and stromelysin-2: differential expression in rheumatoid synovial fibroblasts. Biochemistry 1989;28:8691-8.
48. Windsor LJ, Grenett H, Birkedal-Hansen B, Bodden MK, Engler JA, Birkedal-Hansen H. Cell type-specific regulation of SL-1 and SL-2 genes: induction of the SL-2 gene but not the SL-1 gene by human keratinocytes in response to cytokines and phorbolesters. J Biol Chem 1993;268:17341-7.
49. Gack S, Vallon R, Schaper J, Rüther U, Angel P. Phenotypic alterations in Fos-transgenic mice correlate with changes in Fos/ Jun-dependent collagenase type I expression: regulation of mouse metalloproteinases by carcinogens, tumor promoters, cAMP, and Fos oncoprotein. J Biol Chem 1994;269:10363-9.
50. Rajewsky K. A phenotype or not: targeting genes in the immune system. Science 1992;256:483.
51. Zucker S, Lysik RM, Zarrabi MH, Greenwald RA, Gruber B, Tickle SP, et al. Elevated plasma stromelysin levels in arthritis. J Rheumatol 1994;21:2329-33.
52. Shingu M, Obata K, Ezaki I, Tomari K, Fujikawa Y, Wada T, et al. Stromelysin-1 (MMP-3) level in the sera from patients with rheumatoid arthritis and other connective tissue diseases - clinical significances in early onset rheumatoid arthritis. Ryumachi 1995;35:15-24.
53. Horn JT, Bendele AM, Carlson DG. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol 1988;141:834-41.
54. Horn JT, Gliszczynski VL, Cole HW, Bendele AM. Interleukin-1 mediated acceleration of type II collagen-induced arthritis: effects of anti-inflammatory or anti-arthritic drugs. Agents Actions 1991;33:300-9.
55. Hom JT, Harlan C, Esteridge T, Gliszczynski VL. Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not resistant mice. Clin Immunol Immunopathol 1992;62:56-65.
56. Killar LM, Dunn CJ. Interleukin-1 potentiates the development of collagen-induced arthritis in mice. Clin Sci 1989;76:535-8.
57. Campion GV. The prospect for cytokine based therapeutic strategies in rheumatoid arthritis. Ann Rheum Dis 1994;53:485-7.
58. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
59. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33:305-15.
60. Phadke K, Carlson DG, Gitter BD, Butler LD. Role of interleukin-1 and interleukin-2 in rat and mouse arthritis models. J Immunol 1986;136:4085-91.
61. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992;89:7375-9.
62. Van den Berg WB, Joosten LAB, Helsen M, van de Loo FAJ. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994;95:234-7.
63. Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C, et al. Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice prevents the associated acute-phase response. Clin Exp Rheumatol 1993;11:515-22.
64. Schorlemmer HU, Kanzy EJ, Langner KD, Kurrle R. Immuno-modulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis. Agents Actions 1993;39:113-6.
65. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
66. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762-6.
67. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
68. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
69. Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, Conn CA, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β-deticient mice. Immunity 1995;3:13-9.
70. Wei X-Q, Charles IG, Smith A, Ure J, Feng G-J, Huang F-P, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995;375:408-11.
71. Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, et al. P1′ biphenylethyl carboxyalkyl dipeptide inhibitors of stromelysin-1 (MMP-3). J Med Chem 1997;40:1026-40.
72. Yocum SA, Lopresti-Morrow LL, Gabel CA, Milici AJ, Mitchell PG. Bafilomycin Al inhibits IL-1 stimulated proteoglycan degradation by chondrocytes without affecting stromelysin synthesis. Arch Biochem Biophys 1995;316:827-35.
73. Andrews HJ, Plumpton TA, Harper GP, Cawston TE. A synthetic peptide metalloproteinase inhibitor, but not Timp, prevents the breakdown of proteoglycan within articular cartilage in vitro. Agents Actions 1992;37:147-54.
74. Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA, et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995;182:449-57.